NASDAQ:EVAX 15 October 2025

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion shares jumped 25% on Oct 14, closing at $7.84, after Merck exercised its option on the EVX-B3 vaccine, paying $7.5 million upfront with up to $592 million in milestones. Evaxion will present two-year Phase 2 data for its AI-designed melanoma vaccine at ESMO on Oct 17. The company also announced an upgrade to its AI-Immunology platform and maintains a “Strong Buy” rating from analysts.

15 October 2025

Artificial Intelligence·Biotechnology·NASDAQ:EVAX·Stock Market

Micron Technology Shares Fall 4% Despite Record Q1 Earnings and Strong Q2 Guidance
March 24, 2026, 5:03 AM EDT. Micron Technology (MU) reported robust Q1 results with revenue rising 57% year-over-year to $13.64 billion and non-GAAP EPS beating estimates by 21% at $4.78. The company forecasted an even stronger Q2, projecting $18.7 billion in revenue and $8.42 earnings per share, backed by sold-out High Bandwidth Memory (HBM) products and expected 68% non-GAAP gross margins. Despite this, shares dropped 4% amid Middle East geopolitical concerns and investor caution over sustaining high margins while scaling capacity. The stock's decline contrasts with broader market gains, highlighting investor skepticism about growth sustainability despite locked-in orders through 2026 and strong demand from AI hyperscale customers.